Evidence map›Paper›PMID 37171598›Full record

Observational studyAnnals of hematology2023

N-Acetylcistein for thrombotic thrombocytopenic purpura: an observational case series study.

Ignacio Español, Juan Diego Leal, Miguel Blanquer, Faustino García-Candel, Angela Heredia, Joaquín Gómez-Espuch, Celia González, Jorge Montserrat, María Sacramento Díaz-Carrasco, Antonio Martínez and 1 more

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ignacio EspañolHematology Department, University Hospital Virgen de la Arrixaca, IMIB-Pascual Parilla, Carretera Madrid-Cartagena s/n, 30120 El Palmar, Murcia, Spain. i.espanol@gmail.com.ORCID http://orcid.org/0000-0001-5145-7711
Juan Diego LealHematology Department, University Hospital Virgen de la Arrixaca, IMIB-Pascual Parilla, Carretera Madrid-Cartagena s/n, 30120 El Palmar, Murcia, Spain.
Miguel BlanquerHematology Department, University Hospital Virgen de la Arrixaca, IMIB-Pascual Parilla, Carretera Madrid-Cartagena s/n, 30120 El Palmar, Murcia, Spain.
Faustino García-CandelHematology Department, University Hospital Virgen de la Arrixaca, IMIB-Pascual Parilla, Carretera Madrid-Cartagena s/n, 30120 El Palmar, Murcia, Spain.
Angela HerediaHematology Department, University Hospital Virgen de la Arrixaca, IMIB-Pascual Parilla, Carretera Madrid-Cartagena s/n, 30120 El Palmar, Murcia, Spain.
Joaquín Gómez-EspuchHematology Department, University Hospital Virgen de la Arrixaca, IMIB-Pascual Parilla, Carretera Madrid-Cartagena s/n, 30120 El Palmar, Murcia, Spain.
Celia GonzálezPharmacy Department, IMIB-Pascual Parrilla, University of Murcia, Murcia, Spain.
Jorge MontserratHematology Department, University Hospital Virgen de la Arrixaca, IMIB-Pascual Parilla, Carretera Madrid-Cartagena s/n, 30120 El Palmar, Murcia, Spain.
María Sacramento Díaz-CarrascoPharmacy Department, IMIB-Pascual Parrilla, University of Murcia, Murcia, Spain.
Antonio MartínezHematology Department, University Hospital Virgen de la Arrixaca, IMIB-Pascual Parilla, Carretera Madrid-Cartagena s/n, 30120 El Palmar, Murcia, Spain.
José M MoraledaHematology Department, University Hospital Virgen de la Arrixaca, IMIB-Pascual Parilla, Carretera Madrid-Cartagena s/n, 30120 El Palmar, Murcia, Spain.
Hospital Universitario Virgen de la Arrixaca · ESUniversidad de Murcia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder. N-Acetylcysteine (NAC) rapidly degrades ultra-large von Willebrand factor multimers by disrupting the disulfide bonds. We report a series of twelve consecutive patients diagnosed with acquired TTP successfully treated with high-dose NAC (150 mg/kg/day) in combination with plasma exchange and steroids. Eight patients also received rituximab. Two patients presented refractory TTP. All patients achieved a quick clinical response in a median time of 5.5 days after starting NAC and are alive after a median follow-up of 29 months. The treatment was feasible and well tolerated. These data provide further evidence of the potential benefit and safety of adding NAC to the standard of care.

Indexed as

Purpura, Thrombotic ThrombocytopenicAcetylcysteineADAMTS13 ProteinHumansPlasma ExchangeRituximabAcetylcysteineADAMTS13 ProteinRituximabAcquired thrombotic thrombocytopenic purpuraDisease treatmentN-Acetylcysteine

Identifiers

PMID37171598
PMCPMC10176284
OpenAlexW4376223964

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.